Stockscreener 앱 받기
3.28
1.20%
-0.04
시간 외 거래:
3.20
-0.08
-2.44%
전일 마감가:
$3.32
열려 있는:
$3.35
하루 거래량:
19,568
Relative Volume:
0.22
시가총액:
$94.66M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.2111
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
-9.89%
1개월 성능:
+12.33%
6개월 성능:
+42.61%
1년 성능:
-11.35%
1일 변동 폭
$3.2133
$3.4706
1주일 범위
$2.89
$3.6088
52주 변동 폭
$1.5201
$16.94
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 382-3281
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
3.28 | 94.66M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. - FinancialContent
Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital - Defense World
Senti Biosciences (SNTI) Maintains Buy Rating with Target Price Unchanged | SNTI Stock News - GuruFocus
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
SNTI: Senti Bio Shares Positive Phase 1 Trial Results for SENTI-202 | SNTI Stock News - GuruFocus
Senti Bio Releases Virtual Investor "What This Means” Segment - The Manila Times
Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 - Nasdaq
Breakthrough Leukemia Treatment: Senti Bio's CAR-NK Therapy Shows Promising Phase 1 Results at AACR 2025 - Stock Titan
Senti Bio to Present at the Citizens JMP Life Sciences Conference - The Manila Times
Breakthrough: Senti Bio's SENTI-202 Shows Promise in Treating Resistant Blood Cancer - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph
Market Momentum Report: Prairie Operating Co (PROP)’s Positive Close at 4.10 - DWinneX
Closing Figures Unveiled: Senti Biosciences Inc (SNTI) Drop -27.20, Closes at 3.64 - DWinneX
An Analysis of Senti Biosciences Inc (SNTI)’s Potential Price Growth - knoxdaily.com
Senti Biosciences reports promising SENTI-202 trial results - Investing.com
SNTI’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall - marketscreener.com
SNTI’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Senti Biosciences, Inc. Reports Additional Positive Preliminary Data from A Phase 1 Clinical Trial of SENTI-202 - marketscreener.com
Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML - marketscreener.com
Senti Biosciences Reports Positive Preliminary Data from Phase 1 Trial of SENTI-202 in Relapsed/Refractory AML at AACR Annual Meeting 2025 - Nasdaq
Breakthrough: Senti Bio's Novel Cell Therapy Achieves 71% Response Rate in Hard-to-Treat Blood Cancer - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025 - geneonline.com
Senti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual Meeting - Nasdaq
New Cancer Treatment Data: Senti Bio's SENTI-202 Phase 1 Results Coming at AACR Conference - Stock Titan
Senti Bio Participates in a Virtual Investor KOL Connect Segment - The Manila Times
Senti Biosciences Releases KOL Segment Featuring Dr. Stephen Strickland on Advances in Acute Myeloid Leukemia Research - Nasdaq
Top Leukemia Experts Reveal Latest AML Treatment Breakthroughs: Senti Bio's SENTI-202 Program in Focus - Stock Titan
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment - The Manila Times
Gene Circuit Pioneer Senti Bio Opens Access: CEO & CMO Host Live Investor Q&A - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Bio appoints new scientific advisory board member By Investing.com - Investing.com South Africa
Senti Bio appoints new scientific advisory board member - Investing.com
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. - GlobeNewswire
Senti Bio Joins Webull Corporate Connect Service Platform - The Manila Times
Senti Biosciences joins Webull’s Corporate Connect Service By Investing.com - Investing.com Australia
Senti Biosciences joins Webull’s Corporate Connect Service - Investing.com
Clinical-Stage Biotech Senti Bio Launches New Investor Hub on Webull - Stock Titan
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Groundbreaking Clinical Trial Data: SENTI-202 Shows Promise for Hard-to-Treat Blood Cancer - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Virtu Financial LLC Acquires Shares of 13,356 Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Biosciences Files Shelf for 52.9 Million Shares - MarketScreener
Senti Biosciences Files For Shelf Of Up To 52.9 Mln Shares Of Common Stock By Selling StockholdersSEC Filing - Marketscreener.com
Senti Bio Reports Promising Trial Results and Financial Growth - TipRanks
Senti Biosciences Inc. (SNTI) reports earnings - Quartz
Senti Biosciences, Inc. SEC 10-K Report - TradingView
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - The Manila Times
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and ... - The Bakersfield Californian
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
센티 바이오사이언시스 주식 (SNTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.39%
3.66%
자본화:
|
볼륨(24시간):